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A B S T R A C T
Introduction: Tenofovir disoproxil fumarate (TDF) is widely recommended for treatment of chronic hepatitis B
virus (HBV) infection because it is safe, affordable and has a high genetic barrier to resistance. TDF resistance
associated mutations (RAMs) have been reported, but data are limited, particularly for Africa. We set out to
identify potential RAMs in individuals with detectable HBV viraemia on TDF treatment.
Methods: We recruited adults with chronic HBV infection from Cape Town, South Africa, identifying individuals
with a TDF resistance phenotype, defined as persistent HBV vireamia despite> 12 months of TDF treatment. We
sequenced HBV DNA using MiSeq Illumina with whole genome target enrichment, and sought potential TDF
RAMs, based on a pre-defined list of polymorphisms.
Results: Among 66 individuals with chronic HBV (genotypes A and D), three met our clinical definition for TDF
resistance, of whom two were coinfected with HIV. In one participant, the consensus HBV sequence contained
nine polymorphisms that have been described in association with TDF resistance. Significant treatment non-
adherence in this individual was unlikely, as HIV RNA was suppressed. TDF RAMs were also present in HBV
sequences from the other two participants, but other factors including treatment non-adherence may also have
had a role in failure of HBV DNA suppression in these cases.
Discussion: Our findings add to the evidence that RAMs in HBV reverse transcriptase may underpin a TDF re-
sistant phenotype. This is the first time these RAMs have been reported from Africa in association with clinical
evidence of TDF resistance.
1. Introduction
Tenofovir disoproxil fumarate (TDF) is a first line nucleoside ana-
logue (NA) agent used to treat chronic hepatitis B virus (HBV) infection
[1,2]. Although the genetic barrier to TDF resistance is high [1,2],
recent reports suggest possible HBV resistance to TDF [3,4]. A review of
potential TDF resistance associated mutations (RAMs) highlights sig-
nificant gaps and limitations in the current literature, demonstrating
the need for further investigation [5].
TDF is also used as antiretroviral therapy (ART) for HIV [6,7]. Thus,
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in settings where HIV is widespread, population exposure to TDF is
high, raising the potential risk of selection of resistance in both HIV and
HBV [7]. Monitoring HIV viraemia in coinfected patients receiving
TDF-based regimens provides insights about treatment compliance, as
HIV suppression is a surrogate for adherence to therapy.
Improved insight into the prevalence and clinical significance of
HBV RAMs is essential; selection and dissemination of TDF resistant
HBV would limit the success of antiviral therapy for individual patients,
and may undermine efforts to curb transmission in pursuit of elimina-
tion targets [8–10]. We identified patients in whom concerns about
possible drug resistance were raised on account of persistent HBV vir-
aemia despite TDF therapy. Sequencing HBV confirmed the presence of




Adults were enrolled into a cross-sectional cohort of CHB at
Tygerberg Hospital, Cape Town, South Africa (‘OxSAHep’ HBV study),
as previously described [11]. All participants provided written in-
formed consent. Ethics approval was provided by the University of
Oxford Tropical Research Ethics Committee (ref. OXTREC 01–18) and
Stellenbosch University Human Research Ethics Committee (HREC ref.
N17/01/013). We identified patients with CHB in whom HBV viraemia
was ≥20,000 IU/mL despite being on TDF treatment for> 12 months
(Fig. 1).
South African guidelines for HBV treatment recommend use of la-
mivudine (3TC), entecavir (ETV) or TDF [12,13]. In practice, TDF is
most frequently used, as 3TC use is limited by drug resistance, and ETV
is expensive and not widely available.
2.2. Deep sequencing and identification of RAMs
We extracted HBV DNA from plasma using a NucliSENS magnetic
extraction system (BioMérieux), and used a published protocol to
generate fully double stranded HBV genomes [14,15]. We purified DNA
and prepared sequencing libraries followed by whole genome target-
enrichment with custom-designed HBV probes. We sequenced the
samples on an Illumina Mi-Seq using a v3 300bp paired end kit and
analysed using Tanoti v1.3 [16] with genotyping and variant calling
performed using the HBV-GLUE resource [17].We called TDF RAMs
using a catalogue of 37 RAMs in HBV reverse transcriptase (RT) [5,7].
3. Results
3.1. Phenotypic evidence of TDF resistance
Among 66 adults with CHB, we identified three with HBV DNA viral
load (VL) ≥20,000 IU/mL, despite therapy with TDF for ≥12 months
(Figure 1), of whom two were co-infected with HIV. Both co-infected
patients were treated with 3TC and Emtricitabine (FTC) in addition to
TDF. In patient 209, HIV RNA suppression provides evidence for
treatment adherence (Figure 2A Figure 2A ), increasing the probability
that HBV drug resistance is genuinely present. In contrast, in patient
258, both HIV and HBV remained detectable, suggesting a possible
incomplete adherence to therapy, with or without drug resistance in
one or both viruses (Figure 2B Figure 2B).
A third case (ID 289) was HIV negative. HBV viral suppression oc-
curred after a cumulative 30 months on treatment (Figure 2C Figure
2C). This individual also had concurrent large flares in liver enzymes
(Figure 2 C Figure 2C).
3.2. Genomic evidence of TDF resistance
We derived full-length HBV genome sequences for all three patients,
although with varying depth of coverage, identifying genotype-A in two
cases and -D in the third (Table 1). The consensus sequences all con-
tained RAMs that have been previously described in association with
TDF resistance .
In HBV sequences from patient 209, we observed nine potential TDF
RAMs. Among these, four polymorphisms (R153W, V173L, L180M, and
M204V), have the strongest evidence base [5]. M204I/V and L180M are
best recognised in association with 3TC resistance [19], but they may
also be part of a combination of polymorphisms that underpins TDF
resistance as there was no sustained viral suppression. In patients 258
and 289, six and five putative TDF RAMs were observed, respectively.
At a deep sequence level, the RAMs we observed in all three patients
were present in> 95 % of HBV reads.
For each potential RAM identified in our HBV sequences we re-
viewed the prevalence of the variants in published HBV sequences
(Table 2). In all three cases, a number of potential TDF RAMs actually
represent the most common residue in this genotype [20]. Of note, for
Fig. 1. Selection of participants with chronic HBV infection
for viral sequencing to identify tenofovir disoproxil fumarate
(TDF) resistance associated mutations (RAMs). Adults at-
tending clinical follow-up in Cape Town, South Africa, were
enrolled over a period of one year. Three adults with persis-
tent viraemia despite> 12 months of TDF therapy are in-
dicated in the blue box. Of these one had a phenotypic profile
and HBV sequence data to support TDF resistance (orange
box); two others had possible TDF resistance RAMs in HBV
sequences but other factors including non-adherence to
therapy may have contributed to persistent viraemia (yellow
box). (For interpretation of the references to colour in this
figure legend, the reader is referred to the web version of this
article).
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patient 289, four of five TDF RAMs are actually the most common re-
sidue at the site for genotype-A.
4. Discussion
4.1. Summary of findings
We present the first evidence of potential TDF resistance in adults
with CHB in Africa. The three patients presented reflect different
phenotypes, with one case (ID 209, Figure 2A Figure 2A) representing
particularly strong evidence for HBV resistance to TDF. The other two
cases illustrate the difficulties in discriminating between drug re-
sistance and incomplete adherence, and may also reflect the long
timelines sometimes associated with viraemic suppression on TDF [21].
These explanations are not mutually exclusive, and may all have a role
in incomplete virologic suppression.
4.2. Interpretation
Patient 209 was treated with both TDF and 3TC, making it likely
that exposure to 3TC resulted in the development of RAMs V173L,
L180M and M204V, possibly setting the scene for the subsequent de-
velopment of cross-resistance to TDF. Although FTC is not part of the
recommended treatment options for CHB, it is widely used for HIV and
has some activity against HBV. Combination TDF and FTC has been
shown to have better viral suppression compared to TDF monotherapy
among treatment naïve individuals with CHB [22], suggesting these
mutations may confer resistance to both drugs.
The precise contribution of these polymorphisms to resistance
Fig. 2. Longitudinal viral load and liver function test distribution of three adults with detectable HBV viraemia>20,000 IU/mL despite ≥12 months prescribed TDF
therapy. Panels A-C plot laboratory parameters over time in three patients. The corresponding clinical data for each patient is shown below in panel D.
Table 1
Summary of patient characteristics and HBV sequence data generated from
three South African adults. All patients had with persistent HBV viraemia
≥20,000 IU/mL despite> 12 months prescription of TDF therapy.
Patient ID 209 258 289
Treatment TDF+3TC+FTC TDF+3TC+FTC TDF
Age range at recruitment 41−50 41−50 61−70
HIV status Positive Positive Negative
Elastography score (kPa) 6.9 5.1 9.1
HBV DNA viral load, log10
IU/mL at time of
sequencing
8.03 6.77 8.18
HIV RNA viral load, log10
copies/mL at time of
sequencing
1.74 4.97 N/A
Median coverage/site 4262 1601 14














Underlined polymorphisms have been reported as RAMs, but occur frequently
in the genotype identified in this patient (see Table 2).
* These RAMs have been identified based on a combination of both in vivo
and in vitro data and are reported in ≥2 independent peer-reviewed sources,
giving them the most stringent evidence base of all the polymorphisms listed
[6].
† These RAMs cause HBV resistance to 3TC [8]. As patient 209 was on both
TDF and 3TC, it is likely that exposure to 3TC resulted in the selection of RAMs
V173L, L180M and M204V.
Table 2
Frequency of putative TDF RAMs in genotype A (n=290) and D (n=566)
HBV sequences downloaded from Hepatitis B Virus Database (HBVdb), https://
hbvdb.ibcp.fr/HBVdb/. 840 genotype A and 958 genotype D sequences were
downloaded on the 20th of November 2018, and the datasets were filtered to
remove highly similar sequences using a 99.5 % similarity threshold, leaving a
total of 290 geno-A and 566 geno-D sequences.
Polymorphism in HBV RT Frequency in genotype A
sequences
Frequency in genotype D
sequences
Y9H 286/ 290 (98.6 %) 556/566 (98.2 %)
L91I 290/290 (100 %) 41/566 (7.2 %)
F122Y/L 8/290 (2.8 %) 82/566 (14.5 %)
H/126Y 225/290 (77.6 %) 4/566 (0.7 %)
R153W 228/290 (78.6 %) 22/566 (3.9 %)
V173L 0/290 (0%) 4/566 (0.7 %)
L180M 7/290 (2.4 %) 13/566 (2.3 %)
M204I/V 7/290 (2.4 %) 25/566 (4.4 %)
S223A 289/290 (99.7 %) 563/566 (99.5 %)
C256S 279/290 (96.2 %) 65/566 (11.5 %)
D263E 1/290 (0.3 %) 111/566 (19.6 %)
V278I 16/290 (5.5 %) 55/566 (9.7 %)
A317S 4/290 (1.4 %) 531/566 (93.8 %)
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remains to be determined with certainty [5]. All putative RAMs iden-
tified in patient 289 occur frequently in genotype-A sequences, making
it uncertain whether drug resistant polymorphisms have been selected
de novo or are part of a founder sequence. This individual also had large
flares in liver enzymes (Figure 2C Figure 2C) that may be evidence of a
host immunological response in parallel with drug therapy accounting
for the reduction in HBV DNA viraemia. Identifying putative RAMs, and
ascertaining their significance to clinical phenotype, is more difficult
when these polymorphisms represent the ‘wild type’ sequence in certain
genotypes (as described for hepatitis C virus [24,25]). There is a
pressing need for more clinical data combined with in vitro data from
assays that can confirm a resistant phenotype.
4.3. Caveats and limitations
The data we present here are limited to only three individuals, with
different clinical phenotypes (Fig. 2). In patient 289, despite a high viral
load we achieved a limited sequencing coverage depth (Table 2).
Incomplete treatment adherence can also result in virological break-
through, and assessment of drug levels in plasma and/or PBMCs could
provide more objective information [23], especially where HIV cannot
be used as a surrogate measure of treatment compliance.
4.4. Summary
As TDF is widely used in Africa as a component of first line ART, it is
possible that the selection of RAMs in HBV is more prevalent than
previously reported [7,12]. Our findings add to the evidence that mu-
tations in HBV RT can underpin a TDF resistant phenotype. This is the
first time these RAMs have been reported from Africa supported by
clinical evidence of TDF resistance. Further investigation is urgently
needed to determine the prevalence and clinical significance of TDF
RAMs, to investigate the role of combination therapy, and to support
the development of new antiviral agents.
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